Particularly, in most of melanoma cases where G1/S transition mediated by the cyclin-CDK4 pathway is defective and has increased dependence on the G2/M checkpoint to induce cell cycle arrest when exposed to DNA damage, SPOPP-3 (1) may have an added advantage in combination with G2/M inhibitors4. Here, CDK4 is linked to melanoma.